Hundreds of women in England diagnosed with a hard-to-treat form of ovarian cancer are set to benefit from a new life-extending drug now available on the NHS. Mirvetuximab soravtansine is a targeted therapy, representing the first new treatment option for ovarian cancer on the NHS in over two decades, offering renewed hope to patients.
This innovative treatment will be offered to women whose ovarian cancer has progressed and is no longer responding to conventional platinum-based chemotherapy. Specifically, it targets cancer cells that express the folate receptor alpha protein, a characteristic found in approximately 30-40% of high-grade serous ovarian cancers. By precisely targeting these cells, the drug aims to minimise damage to healthy tissue, potentially reducing side effects compared to broader chemotherapy.
Ovarian cancer is the sixth most common cancer among women in the UK, with around 7,500 new cases diagnosed each year. Unfortunately, a significant proportion of these cases are diagnosed at an advanced stage, making treatment more challenging. The introduction of mirvetuximab soravtansine is a significant development for patients who have exhausted standard treatment options, offering a chance to extend their lives and improve their quality of life.
The National Institute for Health and Care Excellence (NICE) has previously highlighted the need for new treatment options for ovarian cancer, particularly for those with recurrent or resistant disease. The availability of this drug follows a rigorous assessment process, confirming its clinical effectiveness and cost-effectiveness for use within the NHS. This decision underscores the commitment to bringing innovative therapies to patients where there is a clear unmet need.
For eligible patients, the drug will be administered intravenously, typically in a hospital setting. Clinical trials have indicated that mirvetuximab soravtansine can extend progression-free survival and overall survival in specific patient groups, providing crucial time for women and their families. This advancement is a testament to ongoing research and development in oncology, bringing tangible benefits to those living with advanced cancer.